Who Are We
Cothera Bioscience is a clinical stage biotech company developing therapeutics for previous undruggable oncology targets with high unmet medical needs. The company’s strength is in its clinically validated translational platform exploiting synthetic legality and protein degradation pathways for cancer killing. It was formed by the core founding members of Crown Bioscience, a well-known Contract Research Organization specialized in translational oncology, together with veteran serial entrepreneurs from the Silicon Valley.
Cothera Bioscience has developed a number of innovative anticancer candidates in the field of synthetic lethality, protein degradation and immunotherapy. Cothera Bioscience has applied for multiple international patents covering the drug candidates as well as the i-CR® technology, a powerful clinically validated translational platform in cancer drug screening and MOA discovery. Currently in Phase 2 studies for multiple indications, Cothera’s lead program PC-002 is a first-in-class small molecule drug targeting Myc- mutated tumors. With more than 50% of human cancers showing increased expression, Myc is regarded as one of the most important yet “undruggable” cancer targets. With a unique mechanism of action, PC-002 selectively induces Myc protein degradation and cell apoptosis in Myc-dependent tumors, potentially targeting multiple indications in cancers involving Myc dysregulation.
The company’s second Myc-targeting program is ZTR, a potent oral cyclin-dependent kinase 9 (CDK9) inhibitor with a unique ability to cross the blood-brain-barrier and depletes Myc proteins. ZTR is being developed for the treatment of high-grade gliomas (HGG) and diffuse intrinsic pontine glioma (DIPG), two forms of brain cancer characterized by Myc overexpression.
The company’s third pipeline product, CTB-02, targets colon cancer and non-small cell lung cancer with pan-KRAS mutations. CTB-02 is expected to enter Phase 1/2 clinical trial in Australia in 2021.